Tag Archives: Biogen Idec Inc

Business, Finance, Occupation & Industry

RBCC Targets Companion Diagnostics Opportunities in Booming $232 Billion Personalized Medicine Marke

April 8, 2013 Bartle Doo Leave a comment

RBCC Targets Companion Diagnostics Opportunities in Booming $232 Billion Personalized Medicine Market

NOKOMIS, Fla.–(BUSINESS WIRE)– As Rainbow Coral Corp.’s (OTCBB: RBCC) biotech subsidiary, Rainbow BioSciences, seeks out potentially lucrative new opportunities in the $232 billion personalized medicine market, the company announced today that it will target new innovations in the growing field of companion diagnostics.

The personalized medicine market in the U.S. is ripe for expansion, with PricewaterhouseCoopers predicting that the sector could grow to as much as $452 billion by 2015. One of the fastest-growing fields in the market is companion diagnostics, which could grow to as large as $42 billion by 2015, according to industry analysts TriMarkPublications.com.

The key to that growth will be innovation. Companion diagnostics is the use of genetic variation to chart different patient responses to specific drugs or biologic agents in order to create effective, efficient treatments tailored to a patient’s genetic profile. The emerging field is believed by many medical experts to have an increasingly important role to play in cancer treatments in coming years.

“Companion diagnostics represent the very cutting edge of technology in medicine today,” said RBCC CEO Patrick Brown. “We believe the key to our success is bringing desperately needed new innovations to the market that will improve patient outcomes and reduce healthcare costs. Companion diagnostics offer us the best opportunities to achieve that goal.”

For more information on Rainbow BioSciences’ personalized medicine initiatives, please visit www.rainbowbiosciences.com/investors.html.

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYS: BMY) , Biogen Idec Inc. (NAS: BIIB) , Abbott Laboratories (NYS: ABT) and Amgen Inc. (NAS: AMGN) .

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news …read more

Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

RBCC: New Rainbow BioSciences Website Highlights Impressive Deal Flow

April 2, 2013 Bartle Doo Leave a comment

By Business Wirevia The Motley Fool

Filed under: Investing

RBCC: New Rainbow BioSciences Website Highlights Impressive Deal Flow

NOKOMIS, Fla.–(BUSINESS WIRE)– Last week, Rainbow BioSciences, the biotechnology division of Rainbow Coral Corp. (OTCBB: RBCC), unveiled a new website highlighting its explorations into the multi-billion-dollar drug delivery and genome-mapping market.

To view the new website, please visit www.rainbowbiosciences.com.

In particular, the revamped site details the company’s new partnership with TheraKine Ltd., the developer of a revolutionary, sustained-release drug delivery platform that could soon make local delivery of biologic agents and small molecules safer, more effective and more convenient than ever before. Some experts believe that the worldwide market for the 10 most popular drug delivery technologies (DDTs) alone could grow to $81.5 billion by 2015.

In addition, RBCC is close to partnering with a cutting-edge genome-mapping facility in Houston capable of helping doctors assess genetic variations in patients in order to create more effective, optimized drug treatment plans. The genetic testing sector is one of the fastest-growing segments of the global biotech industry, with some market experts expecting it to reach $2.2 billion by 2017.

“The partnerships that we’re targeting could help usher in a new era of healthcare: personalized medicine,” said RBCC CEO Patrick Brown. “We see big growth in store for this sector, and Rainbow BioSciences’ improved website will help us keep shareholders, potential investors and other interested parties up to date on our latest activities to bring these revolutionary technologies to a pharmacy or clinic near you.”

Rainbow BioSciences is dedicated to developing and marketing new medical and research technologies to compete in a fast-growing industry alongside companies such as Bristol Myers Squibb Co. (NYS: BMY) , Biogen Idec Inc. (NAS: BIIB) , Abbott Laboratories (NYS: ABT) and Valeant Pharmaceuticals International (NYS: VRX) .

For more information on these initiatives, please visit www.rainbowbiosciences.com/investors.html.

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.

Notice Regarding …read more
Source: FULL ARTICLE at DailyFinance

Articles of Interest

Tecfidera, Oral Multiple Sclerosis Drug, Approved By FDA

March 27, 2013 Bartle Doo Leave a comment

By The Huffington Post News Editors

By Toni Clarke
March 27 (Reuters) – U.S. regulators have approved a new multiple sclerosis drug made by Biogen Idec Inc that is widely expected to become the No. 1 oral treatment for the disease, with annual sales of more than $3 billion.
The drug, Tecfidera, activates a chemical pathway in the body known as Nrf2 which helps protect nerve cells from damage and inflammation. It is expected to be launched within days.
Multiple sclerosis is a chronic condition which attacks the central nervous system and can lead to numbness, weakness, paralysis and blindness. It affects more than 2.1 million people worldwide, according to the National Multiple Sclerosis Society.
The U.S. Food and Drug Administration said on Wednesday that the drug may decrease a patient’s white blood cell. White blood cells help protect the body from infection, and while no significant increase in infections was seen during clinical trials of the drug, the agency recommended patients have their white blood cell count assessed before treatment and once a year after that.
Biogen already sells the MS drugs Avonex and Tysabri, which together account for about 30 percent of the market. Teva Pharmaceutical Industries Ltd’s drug Copaxone is the current market leader, with a roughly 29 percent share and annual sales last year of more than $4 billion.
Unlike Copaxone, Avonex and Tysabri, which are injected or infused, Tecfidera comes in the more convenient form of a pill. As such, it will compete with Novartis AG’s MS pill Gilenya, which, though first to market, has been dogged by heart safety concerns. Gilenya holds an 8.5 percent share of the market and generated worldwide sales of $1.2 billion last year.

RBCC: TheraKine Joint Venture Offers Significant Opportunity in Licensing

March 26, 2013 Bartle Doo Leave a comment

By Business Wirevia The Motley Fool

Filed under: Investing

RBCC: TheraKine Joint Venture Offers Significant Opportunity in Licensing

NOKOMIS, Fla.–(BUSINESS WIRE)– Only days after signing a joint venture agreement with cutting-edge drug delivery innovators TheraKine, Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp. (OTCBB: RBCC) is working hard to ensure that the partnership will be a fruitful one. Already, the company is searching for new targets that would benefit from adding licenses for the drug delivery protocols TheraKine and RBCC plan to roll out.

The global market for drug delivery technologies is driven by biologics and medications that can’t be administered effectively through traditional means. Some experts believe that the worldwide market for the 10 most popular drug delivery technologies (DDTs) alone could grow to $81.5 billion by 2015.

In order to capture a piece of that growth, RBCC is seeking out healthcare providers for whom TheraKine’s advanced sustained-release delivery system could yield significant returns for their clients. TheraKine has developed and patented novel, tunable technologies with the potential to enable selective, site-specific drug delivery, allowing for lower drug concentrations and significantly reducing the risk of drug toxicity.

“Licensing this incredible new platform is going to be one of the key opportunities to making this a successful partnership,” said RBCC CEO Patrick Brown. “It’s a top priority for our company moving forward. The potential is limitless.”

Rainbow BioSciences develops and markets new medical and research technology innovations to compete in a fast-growing industry alongside companies such as Bristol Myers Squibb Co. (NYS: BMY) , Biogen Idec Inc. (NAS: BIIB) , Abbott Laboratories (NYS: ABT) and Valeant Pharmaceuticals International (NYS: VRX) .

RBCC is dedicated to delivering new medical research and technologies to a hungry global marketplace. For more information on RBCC‘s initiatives, please visit www.rainbowbiosciences.com/investors.html.

About Rainbow BioSciences

About TheraKine Ltd.

TheraKine Ltd. is …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

RBCC Forms Joint Venture With Cutting-Edge Drug Delivery Company TheraKine

March 20, 2013 Bartle Doo Leave a comment

By Business Wirevia The Motley Fool

Filed under: Investing

RBCC Forms Joint Venture With Cutting-Edge Drug Delivery Company TheraKine

NOKOMIS, Fla.–(BUSINESS WIRE)– As part of a bold expansion into the $60 billion global drug delivery market, Rainbow BioSciences, the biotech division of Rainbow Coral Corp. (OTCBB: RBCC), today announced it has formed a new partnership to solve the problems posed by systemic drug delivery.

RBCC signed a joint venture agreement with TheraKine Ltd., the developer of a revolutionary, sustained-release drug delivery platform that could soon make local delivery of biologic agents and small molecules safer, more effective and more convenient than ever before. The company has developed and patented these novel, tunable technologies with the potential to enable selective, site-specific drug delivery, allowing for lower drug concentrations and significantly reducing the risk of drug toxicity.

Additionally, this new sustained-release technology can also extend the patent life cycles of drugs, giving potential pharmaceutical partners a tremendous market advantage.

“TheraKine’s sustained-release delivery system could allow patients who now need daily injections to instead have one injection every four to six months,” said RBCC CEO Patrick Brown. “We expect the demand for this product to be very high once it’s made available, and RBCC plans to take a real stake in its success.”

Stan Yakatan, TheraKine’s CEO, said, “TheraKine is excited about the opportunity to partner with Rainbow to repurpose drugs with our sustained release technologies.”

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYS: BMY) , Biogen Idec Inc. (NAS: BIIB) , Abbott Laboratories (NYS: ABT) and Amgen Inc. (NAS: AMGN) .

About Rainbow BioSciences

About TheraKine Ltd.

Business, Finance, Occupation & Industry

RBCC: Tech Innovations Drive Big Growth in $60 Billion Drug Delivery Market

March 13, 2013 Bartle Doo Leave a comment

By Business Wirevia The Motley Fool

Filed under: Investing

RBCC: Tech Innovations Drive Big Growth in $60 Billion Drug Delivery Market

NOKOMIS, Fla.–(BUSINESS WIRE)– The next generation of advanced pharmaceutical technologies could be poised to fuel remarkable growth in the $60 billion global drug delivery market, and Rainbow Biosciences—the biotech subsidiary of Rainbow Coral Corp. (OTCBB: RBCC)—plans to be right in the middle of the action.

New drug delivery methods are seen by some pharmaceutical giants as a crucial growth generator, and new innovations are spreading across the healthcare sector. Many experts believe that personalized medicine is the future of healthcare, and customized drug delivery has the potential to drastically change the way value is assessed and compensated in the U.S. healthcare system.

RBCC is working hard to capitalize on the changing drug-delivery paradigm by partnering with key players in the field. The company is now in talks with an emerging company that owns technology with the potential to enable selective, site-specific delivery, allowing for lower drug concentrations and greatly reducing the risk of drug toxicity. In addition to helping millions of patients struggling with chronic conditions, this bold new technology can also extend the patent life cycles of drugs, giving potential pharmaceutical partners a tremendous market advantage.

For more information on Rainbow BioSciences’ current projects, please visit www.rainbowbiosciences.com/investors.html.

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYS: BMY) , Biogen Idec Inc. (NAS: BIIB) , Abbott Laboratories (NYS: ABT) and Amgen Inc. (NAS: AMGN) .

About Rainbow BioSciences

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

RBCC Nears Finalization of Partnership Agreement with Leading-Edge Pharmacogenomics Labs

March 6, 2013 Bartle Doo Leave a comment

By Business Wirevia The Motley Fool

Filed under: Investing

RBCC Nears Finalization of Partnership Agreement with Leading-Edge Pharmacogenomics Labs

NOKOMIS, Fla.–(BUSINESS WIRE)– Rainbow Coral Corp. (OTCBB: RBCC), a biotech company focused on delivering new medical technologies and innovations, today reports its anticipation of partnering with a cutting-edge genome-mapping facility in Houston in the next few weeks.

The genetic testing sector is one of the fastest-growing segments of the global biotech industry, with some market experts expecting it to reach $2.2 billion by 2017. The cutting-edge science of pharmacogenomics is a field of study resulting from the Human Genome Project that seeks to help doctors assess genetic variations in patients in order to create more effective, optimized drug treatment plans.

RBCC sees it as the future of medicine.

“This is the next evolution in personalized medicine,” said RBCC CEO Patrick Brown. “Important differences in drug metabolism and response from person to person are often rooted in our genes. By studying a patient’s genotype, doctors can eliminate the trial-and-error approach to tailoring a safer, more efficient and more effective drug treatment plan.”

RBCC is turning its full attention to the exploration of new promising opportunities now that the company will no longer be partnering with Amarantus Biosciences, which has elected to pursue other opportunites. RBCC wishes Amarantus much success moving forward, and remains open to future partnering opportunities with the company.

In addition to its pharmacogenomics talks, RBCC is also currently working on a joint venture agreement with a privately held drug delivery company that could soon make local delivery of biologic agents and small molecules safer, more effective and more convenient than ever before.

For more information on Rainbow BioSciences’ current projects, please visit www.rainbowbiosciences.com/investors.html.

About Rainbow BioSciences

Business, Finance, Occupation & Industry

11 Must Read Weekend Stock Stories For Monday

March 2, 2013 Bartle Doo Leave a comment

By 24/7 Wall St.

Filed under: Earnings, Market News, Mergers & Acquisitions, Industry News, Economy

24/7 Wall St. has tracked many stocks on the move in the last week. Now it is the weekend and this can be considered your weekend cheat sheet for the stocks you need to have your eye on come Monday morning. We are featuring eleven weekend stock stories. After all, your money matters to us even if the markets are taking the weekend off.

Apple Inc. (NASDAQ: AAPL) has fallen out of favor and is actually getting less coverage now that so much media attention was given to the spending sequestration dilemma in Washington DC. Apple shares hit a new 52-week low on Friday And the stock briefly traded under $430. The $1 billion Samsung judgment has been cut by $450 million on Friday. Apple’s share price is getting closer and closer to what portfolio manager Jeffrey Gundlach had been forecasting as a reversion price. The real question that investors will have on Monday and the rest of the week is whether or not anyone starts to care again.

Barnes & Noble, Inc. (NYSE: BKS) is still in trouble if it stays on its own but new interest from founder Riggio has shares back up again. Barron’s reported over the weekend that Riggio should pay at least $19 per share for the retail unit. The report even gave B&N a combined value for the bookstores and the Nook operations at more than $38 per share.

Berkshire Hathaway Inc. (NYSE: BRK-A) released its annual earnings for 2012 and Warren Buffett released his annual letter to shareholders on Friday. While shares have outperformed other conglomerates in 2012, investors may start to look at that premium over book value compared with this year’s strong performance. Buffett’s stock is also trading up virtually at all-time highs.

Bristol-Myers Squibb (NYSE: BMY) will be in focus on Monday, as will Biogen Idec Inc. (NASDAQ: BIIB) and Shire plc (NYSE: SHPG), after late-Friday news that the $60 billion Big Pharma stock considered these and is considering other companies for large acquisitions. While Biogen hit a new all-time high on the pop, Shire actually rose more as the company may be more acquirable and would be cheaper on a raw dollar basis and is currently cheaper on its relative earnings multiples to buy.

Depomed Inc. (NASDAQ: DEPO) will be on watch as it has an FDA panel meeting regarding its menopause drug, and there appears to be a coin-toss over whether or not this will be a win or loss. Expect shares to be halted all day Monday.

Forestar Group Inc. (NYSE: FOR) was highlighted in Barron’s as “rich assets, cheap shares” for its real estate, energy, water, and timberland assets with shares trading at a whopping 40 percent discount to its net asset value. For whatever it is worth, its consensus analyst price target is $25.67 versus the closing price of $17.56. Investors also need to know that the small cap Forestar pays no dividend currently and that its market …read more
Source: FULL ARTICLE at DailyFinance

Bartle Doo Article Archives

Tag Archives: Biogen Idec Inc

RBCC Targets Companion Diagnostics Opportunities in Booming $232 Billion Personalized Medicine Marke

RBCC: New Rainbow BioSciences Website Highlights Impressive Deal Flow

Tecfidera, Oral Multiple Sclerosis Drug, Approved By FDA

RBCC: TheraKine Joint Venture Offers Significant Opportunity in Licensing

RBCC Forms Joint Venture With Cutting-Edge Drug Delivery Company TheraKine

RBCC: Tech Innovations Drive Big Growth in $60 Billion Drug Delivery Market

RBCC Nears Finalization of Partnership Agreement with Leading-Edge Pharmacogenomics Labs

11 Must Read Weekend Stock Stories For Monday

Articles Archive